Saturday / May 17. 2025
menu-logo menu-logo
brand-logo
Subscribe
Subscribe
Saturday / May 17. 2025
  • Read
    • Daily News
      • Financial
      • Insights
      • U.S.
      • International
    • Digital Issue
    • Executive Announcements
    • Cover Stories
    • Feature Articles
      • Exclusive Interviews
    • International Focus
    • Company Spotlights
    • Forward Thinking
    • Legal Briefs
    • Insights from the Outside
    • For You | For Your Field
    • Working Smart
  • Listen & Watch
    • Direct Approach Podcast
    • SHIFT podcast
    • The DSN Podcast
  • Attend
    • DSU Europe 2025
    • DSU Fall 2025
  • Achieve
    • Global 100 List
    • Bravo Awards
    • Best Places to Work
    • Legends
  • Research
    • Stock Watch
    • The DSN Guide
    • Supplier Directory
    • Stock Ticker
    • Resources
  • Engage
    • Supporter Program
    • VIP Text Alerts
  • About
    • About DSN
    • Subscribe
    • Advertise
    • Connect
  • Search
Subscribe

NewAge Makes Breakthrough Scientific Discovery

BY DSN Staff Writer | October 12, 2021 | read / Daily News

NewAge, Inc. announced it has discovered and isolated the mechanism of action to block spike proteins from binding to cells in the human body. The company describes this discovery as “breakthrough science” and intends to leverage it within its own product portfolio, as well as partnering with other medical, research, pharma companies and health systems to make the benefits of this finding more widely available. 

“We have more than 200 patents, cooperative research studies, and peer-reviewed papers on NewAge’s Tahitian NONI® (NONI) products and this new discovery not just adds to the body of research, but brings our insights into the benefits for consumers to an important new level,” said Brett West, Chief Scientist at NewAge. “We have now been able to measure the ability of NONI and its major phytonutrients to block the binding of the spike proteins to cellular membranes. Using enzyme-linked immunosorbent assays (ELISA) to detect the competitive inhibition of spike protein to Angiotensin II Receptors (ACE-2) binding by NONI, NewAge scientists uncovered that NONI inhibited the ability of the spike proteins to bind ACE-2 by approximately 70%.” 

The company reported their findings in an abstract titled “Anti-viral properties of Morinda citrifolia (NONI) fruit juice” and presented during the Functional Foods and Coronavirus Disease (COVID-19) session of the 29th International Conference of the Functional Food Center, a conference that gathers experts in medicine and biology and industry to discuss the usage of bioactive compounds for immune support and health. 

“Presenting at the FCC conference is great recognition for NewAge and a really big deal,” said Deanna Latson, Chief Product Officer at NewAge. “An even bigger deal is our new discovery, one of the magnitude that would normally be expected to come from major pharma companies, research institutes or health systems. The amount of research and scientific data that goes into being able to present findings of this nature is an arduous hurdle, and the significance of NewAge’s new discovery and the impact it may have on immune health has never been more critical and timely given today’s environment.” 

Posted in Daily News and tagged Brett West, Deanna Latson, NewAge.
Related Articles
BODi Reports Q1 Financial Results for 2025 May 16, 2025

BODi Reports Q1 Financial Results for 2025

Read more
4Life Becomes Founding Executive Member of UNPA May 15, 2025

4Life Becomes Founding Executive Member of UNPA

Read more
FTC Click-to-Cancel Rule Deferred May 14, 2025

FTC Click-to-Cancel Rule Deferred

Read more
brand-logo
The News You Need.
The Name You Trust.
Subscribe

Breaking global news, emerging trends and powerful stories conveniently curated to help direct selling executives stay informed, engaged and a step ahead.

  • Read
  • Listen & Watch
  • Attend
  • Achieve
  • Research
  • About
  • Connect
5717 Legacy Drive
Suite 250
Plano, Texas 75024
info@directsellingnews.com
Copyright 2025 Direct Selling News | All Rights Reserved
  • Privacy Policy
  • Terms of Use
  • Advertise
  • Subscribe
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT